Halozyme Therapeutics (HALO) Stock Overview
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
HALO Community Fair Values
Create NarrativeSee what 112 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Halozyme Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$69.82 |
| 52 Week High | US$82.22 |
| 52 Week Low | US$51.06 |
| Beta | 0.88 |
| 1 Month Change | 8.13% |
| 3 Month Change | 3.65% |
| 1 Year Change | 29.66% |
| 3 Year Change | 101.09% |
| 5 Year Change | 77.30% |
| Change since IPO | 1,582.41% |
Recent News & Updates
Narrative Update • May 28
HALO: ENHANZE Deals And Buybacks Will Support 2026 Royalty Visibility
Analysts have nudged their fair value estimate for Halozyme Therapeutics up by $4 to $96, reflecting updated views on growth, margins, and a slightly higher assumed future P/E multiple following recent shifts in Street price targets. Analyst Commentary Recent Street price target changes for Halozyme Therapeutics have pulled in different directions, but taken together they still point to ongoing interest in the stock's execution and earnings power.Seeking Alpha • May 20
Halozyme Therapeutics: Royalty King
Summary Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028 guidance, and announced a new $1 billion share repurchase program. HALO trades at a significant discount to historical and sector valuations, despite maintaining >75% gross margins and strong free cash flow. I estimate HALO's fair value at $74.30/share, underpinned by double-digit royalty growth, high returns on capital, and a strong product pipeline. Read the full article on Seeking AlphaRecent updates
Narrative Update • May 28
HALO: ENHANZE Deals And Buybacks Will Support 2026 Royalty Visibility
Analysts have nudged their fair value estimate for Halozyme Therapeutics up by $4 to $96, reflecting updated views on growth, margins, and a slightly higher assumed future P/E multiple following recent shifts in Street price targets. Analyst Commentary Recent Street price target changes for Halozyme Therapeutics have pulled in different directions, but taken together they still point to ongoing interest in the stock's execution and earnings power.Seeking Alpha • May 20
Halozyme Therapeutics: Royalty King
Summary Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028 guidance, and announced a new $1 billion share repurchase program. HALO trades at a significant discount to historical and sector valuations, despite maintaining >75% gross margins and strong free cash flow. I estimate HALO's fair value at $74.30/share, underpinned by double-digit royalty growth, high returns on capital, and a strong product pipeline. Read the full article on Seeking Alpha
Narrative Update • May 01
HALO: Future Upside Will Rely On Expanding ENHANZE And Hypercon Collaborations
Analysts have lifted their average price target for Halozyme Therapeutics by roughly $1 per share, reflecting updated views on fair value that factor in expectations for royalty-driven revenue, ENHANZE partnerships, and progress with acquired subcutaneous technologies. Analyst Commentary Recent Street research on Halozyme Therapeutics centers on how royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms might support the current valuation and future execution risk.Narrative Update • Apr 17
HALO: Future Upside Will Come From Expanding ENHANZE And Hypercon Royalty Pipeline
Narrative Update The updated analyst price target for Halozyme Therapeutics moves modestly higher to align with recent Street targets in the $75 to $94 range, as analysts point to strong quarterly results, positive guidance, expanding ENHANZE partnerships and progress on acquired subQ platforms as key supports for their assumptions. Analyst Commentary Recent research updates point to a cluster of higher price targets in the $75 to $94 range, anchored in what analysts describe as strong quarterly results, supportive guidance, and expanding partnership and technology pipelines.Narrative Update • Apr 03
HALO: Future Upside Will Depend On Expanding ENHANZE And Hypercon Pipeline Deals
Analysts have raised their average Halozyme Therapeutics price target by about $9 to roughly $87, citing recent Q4 results, higher royalty expectations from ENHANZE partnerships, and added optionality from Hypercon, Surf Bio, and the new Entyvio agreement. Analyst Commentary Recent research updates show a generally constructive tone on Halozyme Therapeutics, with most firms raising their price targets after the Q4 report and the Entyvio ENHANZE deal.Narrative Update • Mar 20
HALO: Future Upside Will Rely On Expanding ENHANZE And Hypercon Deals
Analysts have raised their average price target for Halozyme Therapeutics by around $10 to $15 per share, citing strong recent results, higher royalty expectations, expanding ENHANZE partnerships and new licensing deals as key supports for the updated valuation framework. Analyst Commentary Recent Street research on Halozyme Therapeutics reflects a generally constructive tone, with several firms lifting their valuation frameworks following recent updates on royalties, partnerships and product pipelines.
Narrative Update • Mar 05
HALO: Rich Royalty Hopes May Outrun ENHANZE Partnership And Patent Risks
Analysts have lifted their implied fair value for Halozyme Therapeutics from $56.00 to about $59.56, citing updated assumptions around royalty driven revenue growth, slightly higher profit margins, and a lower future P/E multiple, supported by recent price target increases across several firms following strong quarterly results and new ENHANZE partnerships. Analyst Commentary Street research on Halozyme has generally leaned constructive, with several firms lifting their price targets following what they describe as strong quarterly results, positive guidance and new ENHANZE partnerships.Narrative Update • Feb 19
HALO: Future Upside Will Depend On ENHANZE Deals And Patent Durability
Analysts have lifted their implied fair value estimate for Halozyme Therapeutics to $84.50 from $77.13, citing the new Takeda ENHANZE partnership on Entyvio and refreshed Street price targets of $90 and $75 as key supports for their updated assumptions on growth, margins, and future P/E. Analyst Commentary Street research on Halozyme is mixed but generally supportive, with recent notes focusing on the new Entyvio ENHANZE deal, updated price targets, and how the company fits into broader biotech positioning for 2026.Narrative Update • Feb 05
HALO: ENHANZE Deals And 2026 Outlook Will Support Royalty Visibility
Narrative Update: Halozyme Therapeutics Analysts have made only modest adjustments to their Halozyme Therapeutics models, with slightly higher discount rate and future P/E assumptions and a mixed Street price target backdrop ranging from US$75 to US$90. This reflects both enthusiasm around the new Entyvio ENHANZE deal and differing views on how derisked the long term growth profile really is.Narrative Update • Jan 21
HALO: Future Upside Will Rely On ENHANZE Partnerships And Patent Durability
Analysts have nudged their price target for Halozyme Therapeutics higher, lifting fair value from US$76.00 to about US$77.13 as they factor in updated ENHANZE partnership activity, including the new Entyvio deal, along with refreshed 2026 outlooks from recent research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the new ENHANZE license deal on Entyvio as a positive proof point for Halozyme's partnering model, supporting views that large pharma remains interested in using the platform on blockbuster drugs.Narrative Update • Jan 06
HALO: ENHANZE Expansion May Fall Short Of Optimistic Earnings Expectations
Analysts have increased their fair value estimate for Halozyme Therapeutics from $51 to $56, citing recent price target raises and upgrades that reflect confidence in ENHANZE partnered product expansion and the company’s longer term earnings potential. Analyst Commentary Recent research updates show a mix of optimism and restraint around Halozyme, with a focus on ENHANZE partnered product expansion, model revisions ahead of earnings, and reassessment of reimbursement exposure.Narrative Update • Dec 17
HALO: ENHANZE Expansion And Lower Part B Exposure Will Drive Upside
Analysts have nudged their fair value estimate for Halozyme Therapeutics slightly higher, lifting the price target to $92 from $91 as they factor in stronger than expected ENHANZE-driven growth, earlier than anticipated achievement of over $1B in 2026 EBITDA, and reduced perceived risk from Medicare Part B exposure and patent litigation. Analyst Commentary Bullish analysts highlight that Halozyme is executing ahead of prior long term expectations, with ENHANZE partnered products driving stronger than anticipated revenue and profitability trajectories.Narrative Update • Dec 03
HALO: Future Upside Will Depend On Execution Amid Ongoing Patent Litigation
Analysts have modestly lifted their price targets on Halozyme Therapeutics, citing stronger than expected ENHANZE-driven growth, an accelerated path to more than $1B in 2026 EBITDA, and reduced concerns over Medicare Part B exposure, with recent targets moving as high as $92 from prior levels near $75 to $91. Analyst Commentary Analysts continue to refine their views on Halozyme Therapeutics, with recent research emphasizing both the upside from ENHANZE driven expansion and the remaining uncertainties around competition and reimbursement exposure.Narrative Update • Nov 19
HALO: Future Performance Will Hinge On Execution As Patent Risks Persist
Analysts have raised their price target for Halozyme Therapeutics from $74.44 to $76.00, citing strong quarterly performance, the global expansion of ENHANZE partnered products, and improved visibility around future EBITDA milestones. Analyst Commentary Recent updates from street research provide key insights into how analysts are assessing Halozyme Therapeutics’ outlook following its latest results and business developments.Analysis Article • Nov 06
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) just released its latest quarterly results and things are looking bullish...Narrative Update • Nov 05
HALO: Future Performance Will Depend On Execution Amid Rising Competition And Patent Risks
Analysts have slightly lowered their fair value estimate for Halozyme Therapeutics by $1 to $74.44. This reflects more moderate revenue growth expectations, even as recent price target increases highlight optimism around product expansion and guidance improvements.Narrative Update • Oct 22
Analysts Reassess Halozyme Therapeutics Amid Mixed Sentiment and Slight Valuation Adjustments
Analysts have slightly lowered their fair value estimate for Halozyme Therapeutics, adjusting the target from $76.00 to $75.44 per share. Recent research reflects modest shifts in revenue expectations, cost discipline, and exposure assessments following company updates and external events.Narrative Update • Oct 08
Subcutaneous Biologics Adoption Will Expand ENHANZE's Global Reach
Analysts have raised Halozyme Therapeutics' fair value estimate to $76.00 from $71.67. They cited improved revenue growth expectations, higher profit margins, and upward earnings guidance for 2025 as key factors behind the revised price target.Narrative Update • Sep 23
Subcutaneous Biologics Adoption Will Expand ENHANZE's Global Reach
Analysts have raised Halozyme Therapeutics’ price target to $71.67, reflecting upgraded 2025 EPS guidance driven by robust partner revenue growth and disciplined cost management, though near-term upside remains capped by regulatory uncertainty. Analyst Commentary Bullish analysts cite a substantial 20% increase in 2025 EPS guidance since January, driven by expanding partnered product revenue and strict cost control.Analysis Article • Aug 21
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Rockets 27% But Many Are Still Ignoring The Company
The Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) share price has done very well over the last month, posting an...Narrative Update • Aug 07
Subcutaneous Biologics Adoption Will Expand ENHANZE's Global Reach
With the consensus analyst price target unchanged at $69.44, Halozyme Therapeutics saw a modest improvement in valuation as its future P/E declined, signaling slightly enhanced earnings expectations. What's in the News Halozyme raised 2025 earnings guidance, expecting total revenue of $1,275–$1,355 million (26–33% growth) and royalty revenue of $825–$860 million (44–51% growth) over 2024.Seeking Alpha • Mar 14
Halozyme Therapeutics: Steady Growth In A Challenged Market
Summary Halozyme Therapeutics, Inc. has shown robust growth, with Q4 2024 earnings surpassing expectations and significant revenue increases driven by royalties from partnered products. The company's ENHANZE drug delivery platform enhances existing drugs, generating substantial royalties and milestone payouts, with key products like Darzalex SC and Phesgo key drivers of growth. Despite currently mixed analyst opinions, Halozyme Therapeutics, Inc.'s solid growth prospects and reasonable valuation merit an 'accumulate' rating, especially if the stock dips to the mid $50s. An updated analysis around HALO stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Halozyme: Recent Approvals Alter My Appetite
Summary Halozyme's attempt to acquire Evotec was a bold move to diversify revenue but was ultimately unsuccessful, impacting HALO's stock price. Despite a CRL for Rybrevant, Halozyme's technology saw success with FDA approval of Opdivo Qvantig, promising future royalty revenue. Halozyme's strong clinical track record and projected 20% CAGR in royalty revenue position it for significant growth through 2028. I plan to expedite my HALO accumulation, looking for buying opportunities around the $43.52 threshold, and leveraging market reactions to news. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Summary Halozyme's fabless model, leveraging its ENHANZE technology, has driven significant growth, similar to successful semiconductor companies like NVIDIA and Broadcom. The recent acquisition of Evotec, despite market concerns, is a strategic move to diversify and ensure long-term sustainability beyond ENHANZE's patent lifespan. EVO's unique approach and proprietary features, combined with HALO's strengths, could create new IP licensing opportunities and enhance profitability. Temporary market weakness presents a buying opportunity for long-term investors, supported by potential regulatory tailwinds and continued strong ENHANZE revenue growth. Read the full article on Seeking AlphaShareholder Returns
| HALO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.7% | -2.4% | 0.3% |
| 1Y | 29.7% | 28.3% | 26.2% |
Return vs Industry: HALO exceeded the US Biotechs industry which returned 26.5% over the past year.
Return vs Market: HALO exceeded the US Market which returned 27% over the past year.
Price Volatility
| HALO volatility | |
|---|---|
| HALO Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HALO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HALO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 423 | Helen Torley | halozyme.com |
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
Halozyme Therapeutics, Inc. Fundamentals Summary
| HALO fundamental statistics | |
|---|---|
| Market cap | US$7.86b |
| Earnings (TTM) | US$348.84m |
| Revenue (TTM) | US$1.51b |
23.7x
P/E Ratio5.5x
P/S RatioIs HALO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HALO income statement (TTM) | |
|---|---|
| Revenue | US$1.51b |
| Cost of Revenue | US$351.86m |
| Gross Profit | US$1.16b |
| Other Expenses | US$807.76m |
| Earnings | US$348.84m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.94 |
| Gross Margin | 76.67% |
| Net Profit Margin | 23.13% |
| Debt/Equity Ratio | 976.5% |
How did HALO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 17:11 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Halozyme Therapeutics, Inc. is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| Robert Wasserman | Benchmark Company |
| Clarence Powell | BMO Capital Markets Equity Research |